Sourcing Exosomes in West Virginia
Licensed West Virginia practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. West Virginia buyers need their own professional license and NPI; the wholesale drug distributor license is the supplier’s obligation, not the purchaser’s.
West Virginia made regulatory news in 2026 with HB 4610, a right-to-try expansion for individualized investigational treatments. It is worth knowing what that statute is and what it is not: it is an access law for seriously ill patients, not a regenerative medicine practice act, and the rules that actually shape an aesthetic or wellness practice here are the collaborative agreement framework for nurse practitioners and one of the stricter corporate practice of medicine statutes in the region.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to West Virginia? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | HB 4610 (2026) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from West Virginia
ExaVeyra ships to licensed practices in all 50 states, West Virginia included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active West Virginia professional license in good standing, verifiable through the West Virginia Board of Medicine or the West Virginia RN Board license lookup.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A West Virginia resale exemption certificate through the Tax Division if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
West Virginia licenses wholesale drug distributors through the Board of Pharmacy under the Wholesale Drug Distribution Licensing Act of 1991. Section 60A-8-7 provides that no person or distribution outlet may act as a wholesale drug distributor without first obtaining a license from the Board, and section 60A-8-5 defines wholesale distribution around prescription drugs, sweeping in manufacturers, repackagers, brokers, warehouses, and out-of-state distributors shipping in. The Act expressly conforms to the FDA’s wholesale licensing guidelines at 21 C.F.R. part 205, with the federal guideline controlling in any conflict. The license sits with the distributor, not with the purchasing practice.
W. Va. Code ch. 60A, art. 8 (Wholesale Drug Distribution Licensing Act of 1991), §§ 60A-8-5, 60A-8-7 · West Virginia Board of Pharmacy
West Virginia regenerative-medicine law
West Virginia enacted HB 4610, codified at W. Va. Code ch. 16, art. 51, effective 12 June 2026.
Physicians and their eligible patients under the state Right to Try framework. HB 4610, the Safeguard the Right-To-Try Cutting-Edge Medicine Act, amends West Virginia’s existing Right to Try article to reach individualized investigational treatments alongside conventional investigational products. An eligible patient has a life-threatening or severely debilitating illness attested by a treating physician, has considered the FDA-approved options, has a physician recommendation, and gives written informed consent. This is an access statute for seriously ill patients; it does not create a practice framework for regenerative or aesthetic services, and it does not alter professional licensing, delegation, or facility rules for an ordinary practice.
- Patients with a life-threatening or severely debilitating illness
- Investigational products past phase one of a clinical trial
- Individualized treatments produced for one patient from their own genetic profile
- Physician recommendation and written informed consent
- Hospitalized inpatients excluded
“a drug, biological product or device that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration or a drug, biological product, or device that is unique and produced exclusively for use for an individual patient, based on their own genetic profile, including individualized gene therapy antisense oligonucleotides and individualized neoantigen vaccines”
How this applies to exosomes
West Virginia’s statute in this area is a right-to-try access law, and it is written around investigational drugs, biological products, and devices for patients with life-threatening or severely debilitating illness. It never mentions stem cells, regenerative medicine, or exosomes, so there is no West Virginia definition that reaches acellular extracellular vesicles either to permit or to restrict them, and the right-to-try pathway has nothing to do with the topical aesthetic setting in which licensed practices use exosome products. Those products are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a West Virginia practice
West Virginia is a collaborative state with a statutory exit ramp. A new APRN prescribes only under a collaborative agreement filed with the RN Board, which forwards a copy to the collaborating physician’s licensing board; after three documented years the APRN can apply for independent prescriptive authority. A physician-led practice delegates conventionally, and the strict corporate practice statute means the entity structure above the clinicians deserves as much counsel attention as the delegation below them.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the West Virginia Board of Medicine under W. Va. Code chapter 30, article 3 perform medical acts within their scope and are the source of delegation. In a med spa setting the delegating physician owns the protocols and the good faith evaluation that precede delegated treatments. |
| NP / APRN | West Virginia advanced practice registered nurses practice under W. Va. Code 30-7-15a and 15b. Prescriptive authority requires a collaborative agreement with a physician, with 45 contact hours of pharmacology education behind the application. After at least three years in a duly documented collaborative relationship with prescriptive authority, an APRN may apply to the RN Board to prescribe without a collaborative agreement under 30-7-15b(e). |
| PA | Physician assistants practice in collaboration with physicians under the Board of Medicine’s framework in W. Va. Code chapter 30, article 3E, within an agreed scope, and are among the professionals who may hold medical corporation shares under 30-3-15. |
| RN | Registered nurses practice under W. Va. Code chapter 30, article 7 and the RN Board’s rules, administering treatments on the order of a provider with authority to issue one. An RN does not evaluate the patient independently or select the treatment. |
Good faith examination
West Virginia expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. For an APRN still practicing under a collaborative agreement, the agreement’s written guidelines govern what the APRN evaluates and prescribes. The expectations sit in board rules and the practice acts rather than a named good faith examination statute, so confirm current requirements with the Board of Medicine and the RN Board.
Ownership and clinic licensing
West Virginia codifies a strict corporate practice framework. Under W. Va. Code 30-3-15, a medical corporation practices only under a certificate of authorization from the Board of Medicine, and its shareholders must be licensed physicians, podiatric physicians, or physician assistants; a foreign medical corporation must show equivalent authorization in its home state, a licensed shareholder as its designated representative, and licensure of all shareholders. Cosmetic injectables and energy-based device treatments are the practice of medicine under the Medical Practice Act, so an entity offering them is structured within this framework, typically with a management services organization handling only business operations. Structure with West Virginia counsel.
Cold chain into West Virginia
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in West Virginia order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Charleston | Kanawha | Capital and largest market, with the state’s main clinical concentration. |
| Morgantown | Monongalia | University medical hub in north central West Virginia. |
| Huntington | Cabell | Tri-state market on the Ohio and Kentucky borders. |
| Wheeling | Ohio | Northern panhandle market serving the Pittsburgh corridor. |
| Martinsburg | Berkeley | Eastern panhandle market in the Washington commuter belt. |
| Beckley | Raleigh | Southern regional center. |
- West Virginia orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Practice types we supply in West Virginia
West Virginia licensing and verification
West Virginia Board of Medicine
Licenses physicians and PAs and authorizes medical corporations.
West Virginia RN Board
Licenses APRNs and administers collaborative agreements and prescriptive authority.
West Virginia Board of Pharmacy
Licenses the wholesale drug distributors that ship prescription drugs into West Virginia.
West Virginia sourcing questions
- Does West Virginia have a stem cell law?
- No. West Virginia has enacted no stem cell authorization, disclosure, or documentation statute. What it enacted in 2026 is HB 4610, a right-to-try expansion for individualized investigational treatments, which is an access law for patients with life-threatening or severely debilitating illness rather than a regenerative medicine practice act. Exosome products in West Virginia are governed by federal law, under which no exosome product is FDA approved for administration to humans.
- What does West Virginia HB 4610 actually cover?
- HB 4610, the Safeguard the Right-To-Try Cutting-Edge Medicine Act, effective 12 June 2026, amends the Right to Try article in W. Va. Code chapter 16 to cover investigational products past phase one of a clinical trial and individualized treatments produced for one patient from their own genetic profile, such as individualized gene therapy antisense oligonucleotides and neoantigen vaccines. Eligibility requires a life-threatening or severely debilitating illness, a physician recommendation, and written informed consent. It never mentions stem cells or exosomes.
- What does a West Virginia nurse practitioner need in place?
- A collaborative agreement with a physician for prescriptive authority, under W. Va. Code 30-7-15a and 15b, supported by 45 contact hours of pharmacology education and filed with the RN Board. After at least three years in a duly documented collaborative relationship with prescriptive authority, the APRN may apply to prescribe without a collaborative agreement under 30-7-15b(e).
- Does West Virginia enforce the corporate practice of medicine?
- Yes, in codified form. W. Va. Code 30-3-15 requires a medical corporation to hold a certificate of authorization from the Board of Medicine and requires its shareholders to be licensed physicians, podiatric physicians, or physician assistants, with a parallel pathway for foreign medical corporations. Entities offering medical services, including cosmetic injectables and energy-based treatments, are structured within this framework with West Virginia counsel.
- Does my West Virginia clinic need a wholesale distributor license to buy exosomes?
- No. The wholesale drug distributor license under W. Va. Code 60A-8-7 is held by the distributor shipping into West Virginia, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA has issued a public safety notification about exosome products marketed outside that framework. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to West Virginia?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- West Virginia HB 4610 (2026), enrolled text (accessed 16 October 2026)
- W. Va. Code 60A-8-7, wholesale drug distributor licensing (accessed 16 October 2026)
- W. Va. Code 60A-8-5, wholesale distribution definitions (accessed 16 October 2026)
- W. Va. Code 30-7-15b, APRN prescriptive authority (accessed 16 October 2026)
- W. Va. Code 30-3-15, medical corporations (accessed 16 October 2026)
- West Virginia Board of Pharmacy (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark characterization standard for extracellular vesicles, the baseline this page assumes when it describes what a defensible exosome Certificate of Analysis reports.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current revision of the MISEV standard, supporting this page’s point that EV characterization expectations come from the field’s consensus guidelines rather than from any West Virginia statute.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.